Shots:

• The companies have shared additional P-I safety and immunogenicity data from their ongoing US study of the BNT162b2 against SARS-CoV-2- which has advanced into P-II/III evaluation. Across all populations- BNT162b2 was well tolerated with mild to moderate fever in fewer than 20% of the participants
• In P-I study- BNT162b2 (@7days after the second dose of 30μg) elicited SARS-CoV-2–neutralizing GMTs in younger adults (18-55yrs.) that were 3.8 times the GMT of a panel of 38 sera of SARS-CoV-2 convalescent patients- and in older adults (65-85 years of age)- it elicited a neutralizing GMT 1.6 times the GMT of the same panel
• The companies anticipate commencing the global (Ex- China) P-II/III study of BNT162b2 in up to 30-000 participants that started in Jul’2020- which has to date enrolled 11-000+ patients including in areas with significant SARS-CoV-2 transmission

 Ref: Pfizer | Image: Smartworld

Related News: Pfizer and BioNTech Elicits Strong T-cell Response in P-I/II Study Against COVID-19